row_id,sent_id,text,aspects,polarity,opinion_sample
2,2_0,"Phase 1 was well-tolerated, and treatment-related adverse events (AEs) were all expected and generally dose-dependent, noted on January 2, 2024.","safety,phase",POS,well-tolerated
3,3_0,"Phase 2/3 results missed a primary endpoint on the LS Mean difference (SE) points between treated and placebo, noted January 2, 2024.","endpoint,phase",NEG,missed
8,8_0,"Phase 3 data reported that the trial met its primary endpoint and key secondary endpoints, noted January 3, 2024.","endpoint,phase,financial",POS,met
9,9_0,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.","endpoint,phase",POS,met
10,10_0,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.","endpoint,phase",POS,met
16,16_0,"Additional Phase 1/2 data reported that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide (TC) has achieved a partial response as demonstrated by at least a",phase,POS,achieved
19,19_0,Phase 1 MAD results from 24 healthy volunteers showed that study was well tolerated in participants over the entire dose range and resulted in no safety signals of concern.,"safety,phase",POS,well tolerated
24,24_0,"Phase 2 trial met its primary endpoint, noted January 4, 2024.","endpoint,phase",POS,met
29,29_0,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar",phase,NEU,statistically significant
30,30_0,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar",phase,NEU,statistically significant
31,31_0,"Phase 4 data reported that the trial did not show a statistically significant difference between YUPELRI and Spiriva HandiHaler on the primary endpoint, noted January 5, 2024.",endpoint,POS,statistically significant
46,46_0,"Phase 2b trial met its primary endpoint, noted January 8, 2024.",endpoint,POS,met
51,51_0,Phase 2 data presented at the Biotech Showcase showed that dose was statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after d,phase,POS,statistically significant
53,53_0,"Phase 2a trial did not meet its primary endpoint, noted January 8, 2024.",endpoint,NEG,did not meet
56,56_0,"Phase 2 primary endpoint was met in its randomized, placebo-controlled study, noted on January 8, 2024.","endpoint,phase",POS,met
57,57_0,"Phase 3 trial met its primary endpoint, noted January 8, 2024.","endpoint,phase",POS,met
61,61_0,"Phase 1b data demonstrated potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination developmen",safety,POS,well tolerated
69,69_0,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.","endpoint,safety,phase",POS,met
70,70_0,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.","endpoint,safety,phase",POS,met
71,71_0,"Phase 1 data reported that treatment was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events (TRAEs) reported, noted January 10, 2025.","safety,phase",POS,well tolerated
72,72_0,"Phase 2 32-week interim data reported that 3E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, wi",phase,POS,achieved
74,74_0,"Phase 2b topline data on ATI-1777 2% QD showed a trend toward significance, ATI-1777 2% BID achieved a statistically significant result in the primary efficacy endpoint at week 4, noted January 10, 2",catalyst,POS,achieved
80,80_0,"Additional Phase 3 data reported that at Week 4, a statistically significant greater percentage of patients achieved a 50% reduction in EASI scores (EASI-50), with 69.2% of patients treated with roflu",phase,POS,statistically significant
105,105_0,"Phase 2 data reported that the trial met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups, noted January 18","endpoint,phase",POS,met
110,110_1,Alvotech believes it is in position to receive approval on BsUFA,regulatory,POS,approval
111,111_1,Alvotech believes it is in position to receive approval on BsUFA,regulatory,POS,approval
112,112_1,Alvotech believes it is in position to receive approval on BsUFA,regulatory,POS,approval
113,113_1,Alvotech believes it is in position to receive approval on BsUFA,regulatory,POS,approval
120,120_1,"The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term d",catalyst,POS,achieved
121,121_0,"Phase 3 topline data met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks, noted January 2","endpoint,phase",POS,met
124,124_0,"Phase 3 trial did not meet its primary endpoint, noted January 22, 2024.","endpoint,phase",NEG,did not meet
132,132_0,"Phase 1 data presented at the HEAL Initiative Scientific Meeting reported that the trial successfully met its overdose protection endpoints, noted January 25, 2024.",phase,POS,met
135,135_0,"Phase 2 sub-study data reported statistically significant improvements in measures of cardiac structure and function including left ventricular mass index (-11.4 g/m2 Â±19.4, p=0.03), maximum left vent","pvalue,phase",POS,statistically significant
151,151_0,"Preclinical data demonstrated PALI-2108 to be safe and well tolerated, noted January 29, 2024.",safety,POS,well tolerated
154,154_0,Phase 1 study published at Journal of Parkinson's Disease showed that data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volu,"safety,phase",NEU,well tolerated
155,155_0,"Pk trial met its primary endpoints, noted January 29, 2024.",endpoint,POS,met
159,159_0,"Phase 3 data met the primary endpoint of non-inferiority to augmentin; and demonstrated statistical superiority, noted January 30, 2024.","endpoint,phase",POS,met
160,160_0,"Phase 3 trial data reported a statistically significant improvement on the primary endpoint of the time-weighted sum of the pain intensity difference from 0 to 48 hours (SPID48) compared to placebo, n","endpoint,phase",POS,statistically significant
161,161_0,"Phase 3 trial did not meet its primary endpoint, noted January 31, 2024.","endpoint,phase",NEG,did not meet
170,170_0,"Phase 1 trial initial data presented at the Angiogenesis, Exudation, and Degeneration reported that monthly dosing of KSI-501 was safe and well-tolerated, noted February 3, 2024.","safety,phase",POS,well-tolerated
173,173_0,"Phase 2a data reported that 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period, noted February 5, 2024.","endpoint,safety,financial",POS,met
174,174_0,Phase 1 data showed that it well-tolerated and delivered ustekinumab with high bioavailability.,"safety,phase",POS,well-tolerated
177,177_0,"Company submitted the clinical hold complete response to the FDA for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, noted February 5, 2024.","phase,regulatory",NEG,clinical hold
178,178_0,"Phase 3 study met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older, noted February 5, 2024.","endpoint,phase,financial",POS,met
180,180_0,Phase 1/2 clinical data reported a statistically significant improvements in disease severity were reported in the Fabry Outcome Survey adaptation of the Mainz Severity Score Index (FOS-MSSI) age-adju,phase,POS,statistically significant
181,181_0,"Phase 2 trial met its primary endpoint, noted February 6, 2024.","endpoint,phase",POS,met
183,183_0,"Phase 3 trial was not successful, noted February 6, 2024.",phase,POS,successful
186,186_0,"Phase 1/2 data showed that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile, noted February 6, 2024","safety,phase,financial",POS,favorable safety
192,192_0,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",regulatory,POS,Breakthrough Therapy
193,193_0,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",regulatory,POS,Breakthrough Therapy
195,195_0,"Phase 3 topline data reported that trial met primary endpoint, noted February 7, 2024.","endpoint,phase",POS,met
201,201_1,Safety results showed Ampligen is generally well tolerated in the treatment o,safety,POS,well tolerated
205,205_0,"Phase 2b trial met its primary and secondary endpoints, noted February 9, 2024.","endpoint,financial",POS,met
211,211_0,"Phase 2 study showed that treatment was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events, noted February 12, 2","safety,phase",NEU,well tolerated
212,212_0,"Fast Track designation granted by the FDA on February 12, 2024.",regulatory,POS,Fast Track
217,217_0,"Type-D meeting with the FDA agreed in a that data from a single, adequate, and well-controlled study may form the primary basis of approval of a BLA for isaralgagene civaparvovec, noted February 12, 2",regulatory,POS,approval
222,222_0,"The FDA cleared IND and granted fast-track designation on February 13, 2024.",regulatory,POS,fast-track
223,223_0,"Phase 3 clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile, noted February 13, 2024.","endpoint,safety,phase,financial",POS,met
224,224_0,"Fast track designation granted by the FDA on February 13, 2024.",regulatory,POS,Fast track
234,234_1,"No serious adverse events related to GLSI-100 have been reported to date, noted February 14 2024.",safety,NEG,serious adverse events
240,240_0,"The preclinical study demonstrated successful drug delivery, noted February 14, 2024.",catalyst,POS,successful
245,245_0,"Phase 3 study met the interim primary endpoint, noted February 15, 2024.","endpoint,phase",POS,met
257,257_0,"Phase 3 data reported that the trial showed statistically significant and highly clinically meaningful improvement in progression-free survival (PFS), noted February 19, 2024.","endpoint,phase",POS,statistically significant
258,258_1,"Phase 2a trial placed on clinical hold February 20, 2024.",regulatory,NEG,clinical hold
260,260_0,"Fast Track Designation granted by the FDA on February 20, 2024.",regulatory,POS,Fast Track
261,261_1,"FDA granted Fast Track designation, noted February 20, 2024.",regulatory,POS,Fast Track
266,266_0,"Supplemental approval granted by the FDA, noted February 20, 2024.",regulatory,POS,approval
268,268_0,"Phase 1 trial met its primary endpoint, noted February 21, 2024.","endpoint,phase",POS,met
272,272_0,"Phase 2a data demonstrated a statistically significant benefit in killing ticks compared to placebo, noted February 22, 2024.",catalyst,POS,statistically significant
276,276_0,"Phase 2 open-label extension data reported that both both doses of VTX002 achieved nominal statistical significance for all key secondary endpoints, noted February 22, 2024.","endpoint,phase,financial",POS,achieved
277,277_0,"PDUFA Priority Review date June 27, 2024.",regulatory,POS,Priority Review
280,280_0,"Phase 1/2a approval to commence dosing, noted February 23, 2024.","phase,regulatory",POS,approval
286,286_0,"EAGLE-1 trial met its primary endpoint, noted February 26, 2024.",endpoint,POS,met
287,287_0,"Phase 1 data reported that no severe or serious adverse events were observed in patients treated in Cohort 1, noted February 26, 2024.","safety,phase",NEG,serious adverse events
288,288_0,"Preclinical data reported that treatment achieved comparable or superior efficacy and was shown to have a distinctive multi-modal mechanism of action versus empagliflozin, noted February 26, 2024.",catalyst,POS,achieved
289,289_0,"Approval noted February 26, 2024.",regulatory,POS,Approval
290,290_0,"Phase 1 presented at Tandem Meetings showed that all eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment, noted February",phase,POS,achieved
292,292_0,"Phase 1 updated clinical data at KOL illustrated a potential best-in-class profile: promising efficacy with favorable safety profile in heavily pretreated subjects with late-stage mCRPC, noted Februar","safety,phase",POS,favorable safety
295,295_0,"CRL issued by the FDA, noted February 27, 2024.",regulatory,NEG,CRL
296,296_0,"Phase 2 study met primary and all secondary endpoints, demonstrating reductions in body weight, noted February 27, 2024.","endpoint,phase,financial",POS,met
297,297_0,Phase 2a topline data reported statistically significant improvements (p<0.05) in inflammatory lesions and Investigator's Global Assessment (IGA) score compared to vehicle at Week 12 TP-04 was genera,pvalue,POS,statistically significant
300,300_0,"Phase 2 was well tolerated with anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR), noted February 27, 2024.","endpoint,safety,phase",POS,well tolerated
302,302_0,"Phase 3 final results reported met the first co-primary endpoint in the Intent-to-Treat Analysis, however did not meet the co-primary endpoint showing superiority over vehicle, noted February 28, 2024.Â read less","endpoint,phase",NEU,met
303,303_0,"Phase 2 topline data reported that the trial met its primary endpoint, noted February 28, 2024.","endpoint,phase",POS,met
306,306_0,"Phase 2 topline FL results reported that the trial met its primary endpoint, noted February 28, 2024.","endpoint,phase",POS,met
314,314_0,"Phase 3 top-line data reported that the trial met its primary endpoint, however two key secondary endpoints were specific to colon-in-continuity patients in assessing at least one day/week off PS versus baseline and reaching enteral autonomy at week 48, both of which were not achieved, noted February 29, 2024.Â read less","endpoint,phase,financial",POS,met
324,324_0,Additional Phase 3 data reported that due to the exclusion of data from so many sites the trial missed statistical significance but showed promising directional data on cognitive and functional measures.,phase,NEG,missed
326,326_3,This is the first time that a relapsed/refractory (r/r) AML patient achieved a CR with CDK9 inhibition monotherapy.,endpoint,POS,achieved
326,326_5,"All key study objectives were met regarding pharmacokinetic (PK), pharmacodynamic (PD), safety, and clinical activity, noted March 1, 2024.Â read less",safety,POS,met
332,332_0,"Phase 1 data reported the complete remission was achieved in 64% of patients, with an ORR of 73%, noted March 4, 2024.","endpoint,phase",POS,achieved
345,345_1,"The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24% for people treated with semaglutide 1.0 mg compared to placebo, noted March 5, 2024.Â read less",endpoint,POS,achieved
348,348_0,"Phase 2 trial met the primary endpoint, noted March 5, 2024.","endpoint,phase",POS,met
357,357_0,"Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated, noted March 5, 2024.","safety,phase",POS,well tolerated
362,362_0,"CRL issued by FDA on March 6, 2024.",regulatory,NEG,CRL
370,370_0,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024","endpoint,phase",POS,achieved
371,371_0,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024","endpoint,phase",POS,achieved
376,376_0,"Phase 3 data reported that 97% percent (71/73) of participants treated with Biktarvy achieved viral suppression (HIV-1 RNA < 50 copies /ml) as did 97% (36/37) of participants treated with the DTG-based regimen, noted March 6, 2024.Â read less",phase,POS,achieved
379,379_0,"Phase 2b data 12-week data reported that the trial met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate, noted March 7, 2024.Â read less","endpoint,financial",POS,met
380,380_0,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.","safety,phase",POS,achieved
381,381_0,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.","safety,phase",POS,achieved
382,382_0,"Phase 3 trial met its primary endpoint, noted March 7, 2024","endpoint,phase",POS,met
387,387_0,"Phase 3 topline results did not meet the primary endpoint, noted March 8, 2024.","endpoint,phase",NEG,did not meet
394,394_0,"Phase 2b 24-week data reported that 52% of patients achieved ACR50+PASI100 and up to 61% of patients achieved Minimal Disease Activity (MDA), noted March 10, 2024.",catalyst,POS,achieved
397,397_0,"Phase 3 results data presented at AAD reported that 56.3% of patients who received Otezla through week 52 achieved static Physician Global Assessment (sPGA) response, noted March 11, 2024.",phase,POS,achieved
398,398_0,"Phase 2 additional data reported that more than three quarters (79.2%) of on-treatment patients achieved at least a 50% reduction in AN count (AN50), 54.2% achieved a 75% reduction (AN75), 20.8% achieved 90% reduction (AN90), and 20.8% achieved complete clearance (100% reduction, AN100), surpassing the 56.3%, 25.0%, 12.5% and 12.5% reductions, respectively, in the vehicle control group, noted March 11, 2024.Â read less",phase,POS,achieved
399,399_0,"Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.","endpoint,phase",POS,met
400,400_0,"Phase 1a/1b clinical hold lifted by the FDA, noted March 11, 2024.",regulatory,NEG,clinical hold
404,404_0,Phase 1 clinical update presented at virtual investor event showed that treatment was well-tolerated with no dose-limiting toxicities identified.,"safety,phase",POS,well-tolerated
414,414_0,"CRL announced March 11, 2024.",regulatory,NEG,CRL
415,415_0,"Phase 3 study did not meet its primary endpoint, noted March 11, 2024.","endpoint,phase",NEG,did not meet
420,420_0,"Phase 3 data reported a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo, noted March 12, 2024.","endpoint,phase",POS,statistically significant
423,423_0,"Phase 2 study met its primary endpoint, noted March 13, 2024.","endpoint,phase",POS,met
425,425_0,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024.Â read less",safety,POS,well tolerated
426,426_0,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024.Â read less",safety,POS,well tolerated
427,427_0,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.","safety,phase",POS,well tolerated
428,428_0,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.","safety,phase",POS,well tolerated
430,430_0,"Phase 2b top-line data reported that trial did not meet its primary endpoint, noted March 13, 2024.",endpoint,NEG,did not meet
431,431_0,"Phase 2 top-line data reported that 73% of all patients (22 of 30 patients) met the efficacy endpoint of A4 or GC reduction from baseline at 12 weeks with no treatment-related SAEs reported, noted March 13, 2024.Â read less","safety,sample,phase",POS,met
432,432_0,"Approval announced March 13, 2024.",regulatory,POS,Approval
435,435_0,"Phase 2 achieved statistically significant liver histologic improvement as measured by at least a 2-point reduction in NAFLD Activity Score (NAS), noted March 13, 2024.",phase,POS,achieved
445,445_0,"Phase 3 trial met all primary and secondary pharmacokinetic endpoints, noted March 15, 2024.","phase,financial",POS,met
446,446_0,"Additional Phase 1/2 data reported that all six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and full blood count recovery and briquilimab was well tolerated, noted March 15, 2024.Â read less","safety,phase",POS,achieved
454,454_0,"Phase 2a achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo, noted March 18, 2",catalyst,POS,achieved
459,459_0,"Phase 3 topline data reported that the trial met its primary endpoint, noted March 19, 2024.","endpoint,phase",POS,met
462,462_0,"Phase 3 trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury, noted March 19, 2024.",phase,POS,met
469,469_0,Phase 1/2 clinical data from cohort one (low dose) showed that dosing was well-tolerated with no treatment-emergent SAEs as of 35-week assessment.,"safety,phase",POS,well-tolerated
471,471_0,"Phase 3 trial met primary endpoint, noted March 20, 2024.","endpoint,phase",POS,met
472,472_0,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",catalyst,POS,met
473,473_0,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",catalyst,POS,met
474,474_0,"Phase 2 data reported that eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC, with favorable safety results with no mortality or discontinuations due to advers","safety,phase",POS,favorable safety
475,475_0,"Phase 3 data reported that the trial did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted March 21, 2024.","endpoint,phase",NEG,did not meet
481,481_0,"Phase 2 additional efficacy data showed a statistically significant and durable reduction in ocular pain statistically significant improvement in Tear Film Break-Up Time (TFBUT) throughout the study,",phase,POS,statistically significant
484,484_0,"Full approval announced March 22, 2024.",regulatory,POS,approval
485,485_0,"EUA approval announced March 22, 2024.",regulatory,POS,approval
491,491_0,"Phase 3 trial met its primary endpoint, noted March 25, 2024.","endpoint,phase",POS,met
494,494_0,"Phase 1b/2 proof of concept data reported favorable safety and tolerability profile, mean monthly attack rate reduction of 90-96% for up to 6 months of follow up, noted March 25, 2024.","effect,safety",POS,favorable safety
497,497_0,CRL issued by FDA on March 25 2024.,regulatory,NEG,CRL
498,498_0,CRL issued by FDA on March 25 2024.,regulatory,NEG,CRL
507,507_0,"ANDA Approval from the FDA, noted March 25, 2024.",regulatory,POS,Approval
508,508_0,"CRL issued March 25, 2024.",regulatory,NEG,CRL
509,509_0,"CRL issued March 25, 2024.",regulatory,NEG,CRL
510,510_0,"Phase 2 data reported a 100% complete response rate in the 45 mg cohort, and in the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response, noted March 26, 2024",phase,POS,achieved
512,512_0,Phase 1 data was shown to be safe and well-tolerated in the 28-day study with low rates of GI-related adverse events.,"safety,phase",POS,well-tolerated
513,513_0,"FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately, noted March 26, 2024.",regulatory,POS,approval
522,522_0,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie","endpoint,phase",POS,met
523,523_0,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie","endpoint,phase",POS,met
524,524_0,"Phase 2a initial results demonstrated that a single 10mg dose of BPL-003 was well-tolerated and resulted in a rapid onset and durable antidepressant effect in patients living with TRD, noted March 27,",safety,POS,well-tolerated
528,528_0,"Phase 2 data continue to demonstrate antifungal activity and a favorable safety and tolerability profile, noted March 27, 2024.","safety,phase",POS,favorable safety
536,536_0,"Phase 2 initial data reported that treatment was well-tolerated with an acceptable safety profile, noted March 28, 2024.","safety,phase",POS,well-tolerated
541,541_0,"Phase 1b preliminary data reported that VRON-0200 was safe and well tolerated, with no clinical or laboratory changes of concern, noted March 28, 2024.",safety,POS,well tolerated
547,547_0,"Phase 1b showed that serial procedures were well tolerated without observed dose-limiting toxicity in first cohort, noted March 28, 2024.",safety,POS,well tolerated
548,548_0,"Phase 3 trial met its primary endpoints, noted March 28, 2024.","endpoint,phase",POS,met
550,550_1,"More than 80% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR), noted",catalyst,POS,achieved
552,552_0,"A District Court set aside the injunction and the FDA is no longer enjoined from issuing final approval of Liquidia's New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder, noted Ap",regulatory,POS,approval
556,556_0,Phase 2 study met its primary endpoint.,"endpoint,phase",POS,met
556,556_1,"Despite improved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but it did not meet statistical signifi","endpoint,financial",NEG,did not meet
558,558_0,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",safety,NEG,serious adverse events
564,564_0,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",safety,NEG,serious adverse events
571,571_0,"Phase 2 cohort 4 data reported a a statistically significant reduction of approximately 40% in Rheumatoid Factor in the abiprubart group, noted April 2, 2024.",phase,POS,statistically significant
576,576_0,Phase 3 primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours.,"endpoint,phase",POS,met
581,581_0,"Phase 1/2 has been well tolerated in participants at the doses administered, with no dose-limiting toxicities observed.","safety,phase",POS,well tolerated
589,589_0,Phase 2b study did not meet the pre-specified threshold of pâ‰¤0.2.,catalyst,NEG,did not meet
596,596_0,"Phase 3 trial met the the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted April 5, 2024.","endpoint,phase",POS,met
605,605_0,"FDA Approval on April 5, 2024.",regulatory,POS,Approval
606,606_0,"FDA Approval on April 5, 2024.",regulatory,POS,Approval
614,614_0,"Phase 3 trial met her primary endpoint, noted April 7, 2024.","endpoint,phase",POS,met
615,615_0,"Phase 1/2 trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate, noted April 7, 2024.","endpoint,safety,phase,financial",POS,met
635,635_0,Phase 3 results presented at the ASCRS Conference 2024 included co-Primary symptom endpoint of pain met statistical significance and 7 of 11 secondary symptom endpoints met statistical significance (p,"phase,financial",POS,met
636,636_0,"CRL announced April 8, 2024.",regulatory,NEG,CRL
646,646_0,"Phase 1 data reported that the initial dose level was well tolerated and demonstrated durable objective responses after MT-601 treatment, noted April 8, 2024.","safety,phase",POS,well tolerated
663,663_0,"Preclinical data shared at AACR shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses, noted April 9, 2024.",safety,POS,well-tolerated
668,668_0,"Phase 1 results demonstrated that for the first five patients (three of whom were PDAC patients), QN-302 is overall well-tolerated (no SAE) and they have reported a ""good"" quality of life during the d","safety,phase",POS,well-tolerated
676,676_0,"Phase 3 trial met its primary endpoint, noted April 9, 2024.","endpoint,phase",POS,met
681,681_0,Phase 1/2a trial shared at AACR reported that two of 12 patients achieved stable disease (SD): one patient from Dose level 1 (50 mg) who progressed on Day 112 and one patient from Dose level 3 (200 mg,"sample,phase",POS,achieved
686,686_0,Phase 1 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested in both narcolepsy type 2 and idiopath,phase,POS,statistically significant
691,691_0,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs","safety,phase",POS,manageable safety
692,692_0,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs","safety,phase",POS,manageable safety
696,696_0,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we",safety,POS,well tolerated
697,697_0,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we",safety,POS,well tolerated
699,699_0,Phase 2 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7%.,phase,POS,statistically significant
700,700_0,"Fast track designation granted by the FDA, noted April 11, 2024.",regulatory,POS,Fast track
707,707_0,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,"sample,phase",NEG,did not meet
708,708_0,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,"sample,phase",NEG,did not meet
715,715_0,"Phase 3 data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo, noted April 15, 2024.","effect,phase",POS,statistically significant
716,716_0,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",phase,POS,achieved
717,717_0,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",phase,POS,achieved
718,718_0,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",phase,POS,achieved
719,719_0,"Phase 3 topline results for the 42 mg Cohort achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, noted April 16, 2024.","endpoint,phase,financial",POS,achieved
724,724_0,"Phase 1 additional data presented at AAN demonstrated a favorable safety and tolerability profile in participants with early AD with a relatively low incidence of ARIA-E, noted April 16, 2024.","safety,phase",POS,favorable safety
725,725_0,"Preclinical approval has been received from an independent third-party ethics review board, for human pilot study #2, noted April 16, 2024.",regulatory,POS,approval
730,730_0,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.","endpoint,phase",POS,statistically significant
731,731_0,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.","endpoint,phase",POS,statistically significant
743,743_0,"Phase 3 trial met its primary endpoint, noted April 18, 2024.","endpoint,phase",POS,met
750,750_0,"Phase 3 showed that upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52, not","endpoint,phase",POS,achieved
751,751_0,Phase 2b data presented at AAN reported that PrimeC met safety and tolerability measures as well as statistically significant slowing of disease progression as demonstrated by the ALSFRS-R by 37% (p=0,"pvalue,safety",POS,met
752,752_0,"Phase 1 data presented at AAOM resulted in no treatment-related serious adverse events or dose-limiting toxicities were reported, and all participants completed the study, noted April 18, 2024.","safety,phase",NEG,serious adverse events
753,753_0,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.","endpoint,phase",POS,met
754,754_0,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.","endpoint,phase",POS,met
761,761_0,"Phase 3 additional results exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints, noted April 22,","phase,financial",POS,statistically significant
763,763_0,"CRL issued by the FDA, noted April 22, 2024.",regulatory,NEG,CRL
771,771_0,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Ã...sb","endpoint,phase,financial",POS,met
772,772_0,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Ã...sb","endpoint,phase,financial",POS,met
779,779_0,"Phase 3 trial met its primary endpoint, with results demonstrating therapeutic equivalence between AVT05 and Simponi.","endpoint,phase",POS,met
787,787_0,"Phase 1 data reported that treatment was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events, noted April 24, 2024.","safety,phase",NEU,well tolerated
790,790_0,"Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants, noted April 25, 2024.",catalyst,POS,statistically significant
791,791_0,"Trial met both primary endpoints, noted April 25, 2024.",endpoint,POS,met
795,795_0,"Phase 1 data presented at ECCMID showed that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy v","safety,phase",POS,well tolerated
797,797_0,"Approval announced April 26, 2024.",regulatory,POS,Approval
799,799_0,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe,safety,POS,statistically significant
800,800_0,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe,safety,POS,statistically significant
801,801_0,"Phase 2 data presented at ESCMID reported that the EDP-235 400 mg arm achieved greater mean change in TSS compared with the placebo arm at all time points, noted April 27, 2024.",phase,POS,achieved
802,802_0,"Phase 3 data reported statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy, noted April 29, 2024","endpoint,phase",POS,statistically significant
806,806_0,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.","endpoint,phase",NEG,did not meet
807,807_0,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.","endpoint,phase",NEG,did not meet
811,811_0,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.",safety,POS,well tolerated
812,812_0,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.",safety,POS,well tolerated
822,822_0,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.","endpoint,phase,financial",POS,met
823,823_0,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.","endpoint,phase,financial",POS,met
825,825_0,"MTD data reported that all doses were well-tolerated, noted April 30, 2024.",safety,POS,well-tolerated
827,827_0,"Phase 2/3 top line data reported that NRX-101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduc","pvalue,phase",POS,statistically significant
828,828_0,"Phase 1 topline data reported no vaccine-related serious adverse events (SAEs) and no dose-limiting pharmacotoxicity, noted April 30, 2024.","safety,phase",NEG,serious adverse events
829,829_0,"Phase 1b compassionate use data reported that treatment has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients.",safety,POS,well-tolerated
833,833_0,"Phase 3 trial met its dual primary endpoint of overall survival (OS), noted May 1, 2024.","endpoint,phase",POS,met
834,834_0,"Preclinical successful completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-Î± production in a whole blood (WB) assay, noted May 1, 2024.",catalyst,POS,successful
835,835_0,"Phase 2 30 mg cohort showed a 100% overall response rate in patients with ASXL1 mutation, treatment exhibited strong anti-leukemic activity in 62% of patients with a favorable safety profile across al","safety,phase",POS,favorable safety
839,839_0,"Phase 1 trial successful and complete, noted May 1, 2024.",phase,POS,successful
841,841_0,"Phase 3 data reported a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care, noted May 2, 2024.","endpoint,phase",POS,statistically significant
845,845_0,"Preclinical data reported statistically significant increase in anti-myostatin IgG antibody concentration, where myostatin is a key negative regulator of muscle growth, noted May 2, 2024.",catalyst,POS,statistically significant
846,846_0,Phase 2 trial is well tolerated and has led to encouraging initial efficacy data.,"safety,phase",POS,well tolerated
847,847_0,"Phase 2 trial did not meet its primary endpoint, noted May 3, 2024.","endpoint,phase",NEG,did not meet
848,848_0,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p,phase,POS,statistically significant
849,849_0,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p,phase,POS,statistically significant
851,851_1,"Also, patients achieved similar probabilities of DFS r",catalyst,POS,achieved
852,852_0,"Phase 2 data at APA reported clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints, noted May 4, 2024.","phase,financial",POS,statistically significant
856,856_0,"Phase 2 trial did not meet the pre-specified primary endpoint, noted May 6, 2024.","endpoint,phase",NEG,did not meet
858,858_0,"Phase 2 data reported that treatment was generally well-tolerated and safety was consistent with the known profile, with two patient discontinuations, with both of these patients remain in CR at 10 an","endpoint,safety,phase",POS,well-tolerated
860,860_0,Phase 3 data reported that the trial did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symp,"endpoint,phase",NEU,statistically significant
862,862_0,"Preclinical data reported that a statistically significant (FDR adjusted p-value < 0.05) decline in secondary tumor growth rate was found at days 21, 25 and 29 in those mice that received Alpha DaRT",financial,POS,statistically significant
863,863_0,"Phase 2 final data reported statistically significant improvements in key secondary endpoints, such as progression-free survival, (PFS median 5 months versus 2.9 months; Hazard ratio= 0.58) and statis","endpoint,phase,financial",POS,statistically significant
868,868_0,"Phase 3 data showcased previously disclosed data that demonstrated that setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients, noted May 6, 20","sample,phase",POS,achieved
869,869_0,"BLA accepted for priority review by the FDA, noted May 6, 2024.",regulatory,POS,BLA accepted
870,870_0,"BLA accepted for priority review by the FDA, noted May 6, 2024.",regulatory,POS,BLA accepted
871,871_0,"Fast track designation granted by the FDA, noted May 7, 2024.",regulatory,POS,Fast track
873,873_0,"Phase 2 trial did not meet the primary endpoint, noted May 7, 2024.","endpoint,phase",NEG,did not meet
876,876_0,"Additional Phase 2b data analysis reported a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02), noted May 7, 2024.",pvalue,POS,statistically significant
880,880_0,"Phase 1 trial met its primary and secondary objectives, noted May 8, 2024.","phase,financial",POS,met
881,881_0,"Phase 3 trial data reported that the trial met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo, noted May 8, 2024.","endpoint,phase",POS,met
888,888_0,"Phase 1 data demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall, noted May 8, 2024.","safety,phase",POS,favorable safety
890,890_0,"Phase 3 study did not meet the study's pre-specified statistical criteria for DFS compared to placebo plus adjuvant chemotherapy, with or without radiotherapy, noted May 9, 2024.",phase,NEG,did not meet
898,898_0,"Trial closed due to clinical hold, noted May 9, 2024.",regulatory,NEG,clinical hold
899,899_0,"Trial closed due to clinical hold, noted May 9, 2024.",regulatory,NEG,clinical hold
904,904_0,Preclinical data presented at ARVO showed that intravitreal administration of 4D-175 to non-human primates (NHP) was safe and well tolerated and resulted in robust transgene expression in the retina a,safety,POS,well tolerated
907,907_0,"Phase 2 topline results reported that serious adverse events occurred in 20.7% of TPIP-treated patients and 40.0% of placebo-treated patients, noted May 9, 2024.","safety,phase",NEG,serious adverse events
908,908_0,Phase 2 data reported that sevasemten was well tolerated across all 21 participants and significantly reduced biomarkers of muscle damage associated with exercise with a mean post-exercise reduction o,"safety,sample,phase",POS,well tolerated
912,912_0,"Phase 1 data reported robust and sustained efficacy in adults and the first pediatric patient infusion of RP-L301 was well tolerated, with engraftment achieved at day +15, noted May 19, 2023.","safety,phase",POS,achieved
917,917_0,"Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS), noted May 10, 2024.","endpoint,phase",NEG,did not meet
919,919_0,Phase 3 pre-planned analysis data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria.,"endpoint,phase",POS,met
921,921_0,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",regulatory,POS,Breakthrough Therapy
922,922_0,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",regulatory,POS,Breakthrough Therapy
925,925_0,"Phase 2 trial met primary endpoint, noted May 13, 2024.","endpoint,phase",POS,met
930,930_0,"CRL announced May 14, 2024.",regulatory,NEG,CRL
931,931_0,"Preclinical antiviral activity study resulted in full survival of lethally infected animals was achieved, noted May 14, 2024.",catalyst,POS,achieved
936,936_0,"Phase 2 data reported that 3 of 3 patients who were naÃ¯ve to FLT3i treatment achieved objective response (2 CR, 1 MLFS), noted May 14, 2024.","endpoint,phase",POS,achieved
940,940_0,"Phase 1 data reported that denifanstat was well-tolerated and no safety signals were reported, noted May 15, 2024.","safety,phase",POS,well-tolerated
942,942_0,Phase 1b/2 data to be shared at ESMO Breast Cancer showed that treatment was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of eit,safety,POS,well tolerated
948,948_0,"Phase 3 data reported that trials met their primary endpoints, noted May 16, 2024.","endpoint,phase",POS,met
951,951_0,"Phase 3 data reported that the trial met both dual primary endpoints, noted May 16, 2024.","endpoint,phase",POS,met
959,959_0,"Phase 1b data reported that treatment was well tolerated at the maximum administered dose and treatment with mPH-762 provided robust inhibition of tumor growth, noted May 16, 2024.",safety,POS,well tolerated
976,976_0,"Phase 3 data reported that 70% of patients achieved the composite response endpoint and 25% experienced ALP normalization, noted May 20, 2024.",phase,POS,achieved
981,981_0,"Phase 2 clinical hold removed, noted May 20, 2024.","phase,regulatory",NEG,clinical hold
983,983_0,"Phase 1/2 additional results demonstrate that two 5 Î¼g doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19, no","safety,phase",POS,well-tolerated
986,986_0,"Phase 3 data reported that both trials met its primary endpoints, noted May 21, 2024.","endpoint,phase",POS,met
987,987_0,"Phase 3 topline data study met its primary endpoint with a statistically significant improvement in the time to failure event, noted May 21, 2024.","endpoint,phase",POS,met
992,992_0,"Phase 2 results presented at DDW showed an 83% non-progression rate at 6 months and a statistically significant decrease in overall mean polyp burden at 6 months, noted May 21, 2024.",phase,POS,statistically significant
993,993_0,"Breakthrough Therapy designation (BTD) granted by the FDA, noted May 21, 2024.",regulatory,POS,Breakthrough Therapy
994,994_0,"Phase 3 data showed that nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission, noted May 21, 2024.",phase,POS,achieved
995,995_0,"Phase 2 study met its primary endpoint, noted May 21, 2024.","endpoint,phase",POS,met
996,996_0,"Phase 2 study met its primary endpoint, noted May 21, 2024.","endpoint,phase",POS,met
1008,1008_0,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",safety,NEU,well tolerated
1009,1009_0,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",safety,NEU,well tolerated
1010,1010_0,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",safety,NEU,well tolerated
1017,1017_0,"Phase 1 data published at in video format showed that the study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score",phase,POS,met
1028,1028_0,"Phase 1/2 study as of May 14, 2024, patients receiving the combination of avutometinib and defactinib with gemcitabine and Nab-paclitaxel in dose level 1 cohort achieved a confirmed overall response r",phase,POS,achieved
1035,1035_0,"Phase 1/1b data from ASCO abstract reported that treatment was well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers, noted May 23, 2024.","safety,phase",POS,well tolerated
1049,1049_0,"Phase 2 ASCO abstract showed that treatment administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels, noted May","safety,phase",POS,well tolerated
1051,1051_0,"Preclinical data from ASCO abstract reported that IPH6501, at well-tolerated doses, significantly boosted peripheral NK cell proliferation, drove their accumulation at tumor locations, and effectively",safety,POS,well-tolerated
1061,1061_0,"Phase 1 data from ASCO abstract reported that one patient achieved unconfirmed partial response, and stable disease was observed in 11 patients (24%), noted May 23, 2024.","sample,phase",POS,achieved
1063,1063_0,"NDA and accelerated approval application submitted May 24, 2024.",regulatory,POS,approval
1064,1064_0,Phase 2 clinical efficacy update presented at ASCO abstract showed that monotherapy neoadjuvant treatment was generally well tolerated.,"safety,phase",POS,well tolerated
1066,1066_0,Phase 1 preliminary results from dose escalation in an ASCO abstract shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors,"safety,phase",NEG,DLTs
1079,1079_0,"Phase 1 data from ASCO abstract reported that SVR35 was achieved by all 3 evaluable pts receiving â‰¥10 mg monotherapy, and 3/12 achieved a best response of SVR35, noted May 24, 2024.",phase,POS,achieved
1086,1086_0,"Phase 3 data reported that trial met its primary endpoint, noted May 28, 2024.","endpoint,phase",POS,met
1087,1087_0,"Phase 3 topline data reported that the trial met its primary endpoint, noted May 28, 2024.","endpoint,phase",POS,met
1093,1093_0,"Phase 3 trial met its primary endpoint, noted May 28, 2024.","endpoint,phase",POS,met
1097,1097_0,"Phase 3 data reported a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks, noted May 28, 2024.",phase,POS,statistically significant
1098,1098_0,"Phase 3 data reported that patients treated with Fabhalta in addition to supportive care achieved a 35.1% reduction in proteinuria at 6 months when compared to placebo on top of supportive care, noted",phase,POS,achieved
1101,1101_0,"Phase 1 data from abstract continued to showed that study continues to be well tolerated in the dose expansion portion of the DRAGON trial (Part B), noted May 28, 2024.","safety,phase",POS,well tolerated
1102,1102_0,"Phase 2 data presented at American Epilepsy Society showed azetukalner 20mg achieved clinically meaningful reductions in depression scores on MADRS and HAM-D17 scales, with a 3.04 point difference vs",phase,POS,achieved
1103,1103_1,The data showed NRX-101 achieved similar efficacy to lurasidone on dep,catalyst,POS,achieved
1105,1105_0,Phase 1/2a Safety Review Committee has approved opening enrollment for the 800mg once daily dosing cohort after reviewing favorable safety and pharmacokinetic data from the 550mg cohort.,"safety,phase",POS,favorable safety
